Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Xtant Medical Holdings (XTNT) Capital Expenditures (2016 - 2025)

Xtant Medical Holdings has reported Capital Expenditures over the past 16 years, most recently at $430000.0 for Q3 2025.

Quarterly Capital Expenditures fell 79.56% to $430000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $2.7 million through Sep 2025, down 30.1% year-over-year, with the annual reading at $4.1 million for FY2024, 182.49% up from the prior year.
Capital Expenditures was $430000.0 for Q3 2025 at Xtant Medical Holdings, up from $366000.0 in the prior quarter.
Over five years, Capital Expenditures peaked at $2.1 million in Q3 2024 and troughed at $223000.0 in Q3 2023.
The 5-year median for Capital Expenditures is $484000.0 (2022), against an average of $601842.1.
Year-over-year, Capital Expenditures surged 843.5% in 2024 and then tumbled 79.56% in 2025.
A 5-year view of Capital Expenditures shows it stood at $626000.0 in 2021, then dropped by 29.23% to $443000.0 in 2022, then decreased by 18.06% to $363000.0 in 2023, then soared by 85.12% to $672000.0 in 2024, then crashed by 36.01% to $430000.0 in 2025.
Per Business Quant, the three most recent readings for XTNT's Capital Expenditures are $430000.0 (Q3 2025), $366000.0 (Q2 2025), and $1.2 million (Q1 2025).